Newly published preclinical research signals a substantial conceptual shift with a potential role of photon-counting CT in targeting specific biological processes.
|Articles|January 22, 1997
Toshiba promotes Ariatti and Zimmer
Toshiba America Medical Systems of Tustin, CA, has promoted twoexecutives, John Ariatti and John Zimmer. Ariatti has been namedvice president of sales, while Zimmer moves into Ariatti's formerspot as vice president of marketing. Ariatti joined Toshiba
Advertisement
Toshiba America Medical Systems of Tustin, CA, has promoted twoexecutives, John Ariatti and John Zimmer. Ariatti has been namedvice president of sales, while Zimmer moves into Ariatti's formerspot as vice president of marketing. Ariatti joined Toshiba fromElscint in 1995, while Zimmer previously was director of Toshiba'sCT business unit.
Advertisement
Related to this article
The future of AI in radiology lies in its potential capability to forge connections and enhance efficiencies for enterprise-wide workflows.
In a new podcast episode, Joseph Cavallo, MD, MBA, offered his perspective on AI integration, potential efficiency gains, navigating post-deployment monitoring and how to incorporate AI literacy into radiology resident training.
The FFR-IQ software recently demonstrated a 92.2 percent sensitivity for non-invasive estimation of fractional flow reserve (FFRC) based on coronary CT angiography (CCTA) scans.
A Kaiser score > 5 with breast MRI demonstrated a 97 percent sensitivity and 87.9 percent specificity for predicting malignancy in patients with BI-RADS 0 or 4 presentations on mammography and breast ultrasound, according to a new study.
In a recent interview, Francesco Giganti, MD, PhD, discussed findings from a recent multicenter study demonstrating the ability of an AI software to provide significant clarity to initial PI-RADS 3 assessments on MRI and facilitate a nearly 19 percent reduction in unnecessary prostate biopsies.
The NEXT-Cue AI software, which incorporates analysis of brain MRI scans, reportedly facilitates prognostic assessments of potential progression from mild cognitive impairment (MCI) to Alzheimer’s disease within five years.
In a new podcast episode, Amir Iravani, MD, FRACP, discusses emerging dosimetry data from the COMPETE trial for 177Lu-edotreotide and how it may help facilitate more personalized treatment for patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
Advertisement
Advertisement
Trending on Diagnostic Imaging
1
FDA Clears MRI-Based AI Software for Prognostic Evaluation of Patients with Mild Cognitive Impairment
2
How AI, Theranostics and More Empowered Patients Have Led to Significant Changes in Radiology
3
What’s Next for AI in Radiology?: Facilitating Data Orchestration Over Fragmentation
4
FDA Clears AI-Enabled FFR-IQ Software for Estimating Fractional Flow Reserve from CCTA
5